Phased implementation of screening for cryptococcal disease in South Africa

South African Medical Journal

Volumn 102, Issue 12, 2012, Pages 914-917

  Govender, Nelesh P ^a,b   Chetty, V ^a   Roy, M ^c   Chiller, T ^c   Oladoyinbo, S ^c   Maotoe, T ^d   Stevens, W S ^e   Pinini, Z ^f   Spencer, D ^g   Venter, W D F ^e   Jassat, W ^h   Cameron, D ⁱ   Meintjes, G ^j,k   Mbengashe, T ^l   Pillay, Y ^l  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f Gauteng Department of Health and Social Development   (South Africa)

^g RIGHT TO CARE   (South Africa)

^h Health Systems Trust   (South Africa)

ⁱ Foundation for Professional Development   (South Africa)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l NATIONAL DEPARTMENT OF HEALTH   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; EFAVIRENZ; FLUCONAZOLE; NEVIRAPINE; TUBERCULOSTATIC AGENT;

ALGORITHM; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CONFUSION; CONSCIOUSNESS LEVEL; CRYPTOCOCCAL MENINGITIS; EDITORIAL; FEVER; HEADACHE; HEALTH CARE PERSONNEL MANAGEMENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; LUMBAR PUNCTURE; MONITORING; POINT OF CARE TESTING; PREVALENCE; RECOMMENDED DRUG DOSE; SOUTH AFRICA; TRAINING; TUBERCULOSIS;

EID: 84870653723     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.6228     Document Type: Editorial

References (18)

1. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010;10:67. [http://dx.doi.org/10.1186/1471-2334-10-67.]
2. Jarvis JN, Boulle A, Loyse A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 2009;23(9):1182-1183. [http://dx.doi.org/10.1097/QAD.0b013e32832be0fc]
3. Park BJ, Shetty S, Ahlquist A, et al. Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa. Int J STD AIDS 2011;22(4):199-203. [http://dx.doi.org/10.1258/ijsa.2010.010235]
4. National Institute for Communicable Diseases. GERMS-SA Annual Report 2011, Johannesburg: National Institute for Communicable Diseases, 2012. http://www.nicd.ac.za (accessed 5 September 2012).
5. Jarvis JN, Lawn SD, Wood R, Harrison TS. Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis 2010;51(12):1463-1465. [http://dx.doi.org/10.1086/657405]
6. Jarvis JN, Harrison TS, Govender N, et al. Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa? S Afr Med J 2011;101(4):232-234.
7. Klausner JD, Govender N, Oladoyinbo S, Roy M, Chiller T. Preventing AIDS deaths: cryptococcal antigen screening and treatment. Lancet Infect Dis 2012;12(6):431-432.
8. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011;53(10):1019-1023. [http://dx.doi.org/10.1093/cid/cir613]
9. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012;59(5):e85-91.
10. World Health Organization. Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. Geneva: World Health Organization, 2011. www.who.int/hiv/pub/cryptococcal_disease2011/en/ (accessed 5 September 2012).
11. Jarvis J, Lawn S, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenaemia among patients in an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48(7):856-862. [http://dx.doi.org/10.1086/597262]
12. Roy M, Karstaedt AS, Mendes J, et al. Evaluation of a cryptococcal antigen screening program for HIV-infected persons initiating anti-retroviral therapy in South Africa (Abstract TUAB0503). In Abstracts: 16th International Conference on AIDS and STIs in Africa, Addis Ababa, Ethiopia, 2011:4-8.
13. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤ 100 cells/μL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010;51(4):448-455. [http://dx.doi.org/10.1086/655143]
14. Rajasingham R, Boulware DR. Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4<100 cells/μL. Clin Infect Dis 2012 (in press).
15. South African National AIDS Council. National Strategic Plan on HIV, STIs and TB, 2012-2016. Pretoria: South African National AIDS Council, 2012. http://www.sanac.org.za/index.php/resources/national-strategic-plan (accessed 5 September 2012).
16. Jarvis JN, Govender NP, Chiller T, et al. Cryptococcal antigen screening and pre-emptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care 2012. (in press).
17. McCarthy K, Meintjes G, Arthington-Skaggs B, et al. Guidelines for the diagnosis, management and prevention of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. S Afr J HIV Med 2007; Spring Edition:25-35.
18. National Department of Health. Standard Treatment Guidelines and Essential Drugs List for South Africa: Primary Health Care. Pretoria: National Department of Health 2008. http://www.kznhealth.gov.za/edlphc2008.pdf (accessed 5 September 2012).